Updated review on malignancy-associated venous thromboembolism: Pathogenesis and comparison between various therapeutic modalities

Clicks: 1
ID: 311306
2024
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #163 of 254 articles by views in Yemen Journal of Medicine

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 254 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Venous thromboembolism (VTE) is one of the life-threatening complications in cancer patients, the incidence of which is affected by the patient and malignancy-related variables. Location, type, therapeutic route, stage, grade, and non-supportive treatment of the cancer are the most important VTE risk factors. Patient age, ethnicity, and concomitant genetic or acquired comorbidities or thrombophilias are known risk factors for VTE in cancer. All high-risk cancer patients admitted to hospitals or treated as outpatients should receive VTE prophylaxis. Low molecular weight heparin (LMWH) is the main treatment for active malignant VTE. Vitamin K antagonists and non-vitamin K-dependent oral anticoagulants are used in stable, nonbleeding cancer patients. Anticoagulation should be continued until the cancer is treated or at least controlled. Over the past two decades, randomized clinical and observational trials have improved the pathogenesis and therapeutic knowledge of VTE, but many challenges remain. The lack of an optimal primary prophylaxis method for inpatients and outpatients in oncology and the care of cancer-associated VTE in standard and high-bleeding risk groups are examples for which more clinical research on cancer-associated thrombosis is necessary to address these issues. In this review, we describe the pathogenesis, factors that increase the risk of VTE, and the comparison between the effectiveness of available anticoagulants in the treatment and prevention of VTE in cancer patients.
Reference Key
habas2024updated Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Elmukhtar Habas, Ala Habas, Amnna Rayani, Kalifa Farfar, Eshark Habas, Jamal Alfitori, Mehdi Arrayes, Aml Habas, Abdel-Monem Badawi Yousif, Abdel-Naser Elzouk
Journal Yemen Journal of Medicine
Year 2024
DOI
10.32677/yjm.v3i1.4547
URL
https://yemenjmed.com/abstract?article_id=91
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.